117 related articles for article (PubMed ID: 3490027)
1. Peripheral blood lymphocyte response to exogenous interleukin 2 by PHA-prestimulated and non-PHA-prestimulated cells in patients with cancer.
Mantovani G; Coiana A; Cossu F; Floris C; Proto E; Macciò A; Pisano G; Taglieri G; Puxeddu G; Del Giacco GS
Tumori; 1986 Aug; 72(4):375-82. PubMed ID: 3490027
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 (IL 2) relationships with the cancer-related immunodeficiency: in vitro response to exogenous IL 2 by PHA-activated and non PHA-activated peripheral blood mononuclear cells from cancer patients.
Mantovani G; Coiana A; Massidda A; Proto E; Floris C; Macciò A; Pusceddu G; Del Giacco GS
Diagn Clin Immunol; 1987; 5(2):104-11. PubMed ID: 3497733
[TBL] [Abstract][Full Text] [Related]
3. Role of interleukin-2 (IL-2) in cancer-related immune deficiency: in vitro response to IL-2, production of IL-2, and IL-2 receptor expression in patients with advanced cancer.
Mantovani G; Coiana A; Massidda A; Proto E; Floris C; Macciò A; Pusceddu G; Del Giacco GS
Cancer Detect Prev; 1988; 12(1-6):149-59. PubMed ID: 3263194
[TBL] [Abstract][Full Text] [Related]
4. Production of and response to interleukin-2 in peripheral blood lymphocytes of cancer patients.
Wanebo HJ; Pace R; Hargett S; Katz D; Sando J
Cancer; 1986 Feb; 57(3):656-62. PubMed ID: 3484660
[TBL] [Abstract][Full Text] [Related]
5. Defect in lectin-induced interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's disease.
Soulillou JP; Douillard JY; Vie H; Harousseau JL; Guenel J; le Mevel-le Pourhiet A; le Mevel B
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):935-9. PubMed ID: 3876220
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 activity and the response of peripheral blood lymphocytes in patients with gynecologic malignancies.
Iwano I; Kikuchi Y; Oomori K; Kizawa I; Kita T; Kato K
Cancer Detect Prev; 1988; 12(1-6):583-8. PubMed ID: 3263201
[TBL] [Abstract][Full Text] [Related]
7. Effects of aging on the in vitro response of human lymphocytes to interleukin-2.
Yamashita N; Suzuki H; Maruyama M; Sugiyama E; Yano S
Jpn J Med; 1984 Aug; 23(3):211-5. PubMed ID: 6333539
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of interleukin-2 production in human lymphocytes by two new quinolone derivatives.
Zehavi-Willner T; Shalit I
Lymphokine Res; 1989; 8(1):35-46. PubMed ID: 2785621
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interleukin-2 production by T-helper and natural killer cells.
Chang WC; Fujimiya Y; Casteel N; Pattengale P
Int J Cancer; 1989 Apr; 43(4):591-7. PubMed ID: 2522912
[TBL] [Abstract][Full Text] [Related]
10. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer.
Wanebo HJ; Blackinton D; Kouttab N; Mehta S
Am J Surg; 1993 Oct; 166(4):389-94. PubMed ID: 8214299
[TBL] [Abstract][Full Text] [Related]
11. Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors.
Elliott LH; Brooks WH; Roszman TL
J Immunol; 1984 Mar; 132(3):1208-15. PubMed ID: 6319491
[TBL] [Abstract][Full Text] [Related]
12. Prostaglandin E2 inhibits the generation of phytohemagglutinin-activated killer activity in human peripheral blood lymphocytes.
Yamashita N; Ito M; Suzuki H; Sugiyama E; Yokoyama A; Sato M; Yano S
Anticancer Res; 1986; 6(5):1113-6. PubMed ID: 3492171
[TBL] [Abstract][Full Text] [Related]
13. Prothymosin alpha 1 modulates lymphokine-activated killer cell activity and IL-2 production by peripheral blood lymphocytes from melanoma patients in vitro.
Eckert K; Garbin F; Maurer HR; Büttner P; Garbe C; Czarnecki J
Int J Immunopharmacol; 1995 Jul; 17(7):555-61. PubMed ID: 8586483
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte subsets, phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in sarcoidosis.
Chailleux E; Bignon JD; Peyrat MA; Godard A; Soulillou JP
Thorax; 1985 Oct; 40(10):768-73. PubMed ID: 3877349
[TBL] [Abstract][Full Text] [Related]
15. Diminished interleukin-2 activity production in cancer patients bearing solid tumors and its relationship with natural killer cells.
Rey A; Klein B; Zagury D; Thierry C; Serrou B
Immunol Lett; 1983 Mar; 6(3):175-8. PubMed ID: 6602761
[TBL] [Abstract][Full Text] [Related]
16. Immunologic effects of interleukin 2 in primary immunodeficiency diseases.
Flomenberg N; Welte K; Mertelsmann R; Kernan N; Ciobanu N; Venuta S; Feldman S; Kruger G; Kirkpatrick D; Dupont B; O'Reilly R
J Immunol; 1983 Jun; 130(6):2644-50. PubMed ID: 6222111
[TBL] [Abstract][Full Text] [Related]
17. In vitro correction of the interleukin-2 and interferon-gamma defect in multiple sclerosis.
Vervliet G; Schandené L
Clin Exp Immunol; 1985 Sep; 61(3):556-61. PubMed ID: 3935348
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte activation and cytokine production in autoimmune hemolytic anaemia (AIHA).
Fagiolo E; Abenante L
Autoimmunity; 1996; 24(3):147-56. PubMed ID: 9020407
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis.
Dai SM; Matsuno H; Nakamura H; Nishioka K; Yudoh K
Arthritis Rheum; 2004 Feb; 50(2):432-43. PubMed ID: 14872485
[TBL] [Abstract][Full Text] [Related]
20. Depressed in vitro T cell responses concomitant with augmented interleukin-2 responses by lymphocytes from cancer patients following in vivo treatment with interleukin-2.
Hank JA; Sosman JA; Kohler PC; Bechhofer R; Storer B; Sondel PM
J Biol Response Mod; 1990 Feb; 9(1):5-14. PubMed ID: 2181071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
